New hope to stop dangerous bleeding in transplant patients
NCT ID NCT07442513
Summary
This study is testing if a drug called etamsylate can prevent serious bleeding in patients who have low platelet counts after a stem cell transplant. About 404 adult patients will be randomly assigned to receive either etamsylate or a placebo (inactive substance) to see which is better at preventing bleeding events or death within 30 days. The goal is to see if this drug can safely help control a major risk for people recovering from this intensive treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.